



(12) Translation of
European patent specification

(11) NO/EP 3431477 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 491/052 (2006.01)
A61K 31/4188 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.12.14
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.10.14
(86)	European Application Nr.	18175400.3
(86)	European Filing Date	2012.11.16
(87)	The European Application's Publication Date	2019.01.23
(30)	Priority	2011.11.16, US, 201161560654 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(62)	Divided application	EP2907816, 2012.11.16
(73)	Proprietor	Gilead Pharmasset LLC, 333 Lakeside Drive, Foster City, CA 94404, USA
(72)	Inventor	BACON, Elizabeth, 1218 Floribunda AvenueApt. 8, Burlingame, CA 94010, USA COTTELL, Jeromy, 701 Baltic Circle719, Redwood City, CA 94065, USA KATANA, Ashley Anne, 2201 Bridgepoint Parkway205, San Mateo, CA 94404, USA KATO, Darryl, 223 Connecticut Street, San Francisco, CA 94107, USA KRYGOWSKI, Evan, 2231 California StreetNW 507, Washington, DC 20008, USA LINK, John, 74 Prospect Avenue, San Francisco, CA 94110, USA TAYLOR, James, 100 State Street, San Mateo, CA 94401, USA TRAN, Chinh Viet, 10322 Baron Drive, San Diego, CA 92126, USA MARTIN, Teresa Alejandra Trejo, 3701 Naughton Ave, Belmont, CA 94002, USA YANG, Zheng-Yu, 338 El Carmelo Avenue, Palo Alto, CA 94306, USA ZIPFEL, Sheila, 22 N. San Mateo DriveApt. 205, San Mateo, CA 94401, USA
(74)	Agent or Attorney	OSLO PATENTKONTOR AS, Hoffsvæien 1A, 0275 OSLO, Norge

(54) Title **CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS**


(56) References
Cited: WO-A1-2011/028596
 WO-A1-2010/096777
 WO-A1-2011/066241
 WO-A2-2012/068234
 WO-A1-2010/062821


WO-A1-2011/087740


Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>


Patentkrav


1. Forbindelse med formel:


















eller et farmasøytisk akseptabelt salt derav.


2. Forbindelse med formel:














3. Farmasøytisk sammensetning omfattende forbindelse eller farmasøytisk akseptabelt salt derav ifølge krav 1 og minst en farmasøytisk akseptabel bærer.

5 4. Farmasøytisk sammensetning ifølge krav 3, videre omfattende en nukleosid- eller nukleotidinhibitor av NS5B-polymerase.

5. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge krav 1 for anvendelse i en fremgangsmåte for behandling av hepatitt C.

10

6. Forbindelse eller farmasøytisk akseptabelt salt derav for anvendelse ifølge krav 5, i kombinasjon med et nukleosid eller nukleotidinhibitor av HCV NS5B-polymerase.

7. Farmasøytisk sammensetning omfattende en forbindelse ifølge krav 2 og minst en farmasøytisk akseptabel bærer.
8. Farmasøytisk sammensetning ifølge krav 7, videre omfattende en nukleosid-
5 eller nukleotidinhibitor av NS5B-polymerase.
9. Forbindelse ifølge krav 2 for anvendelse i en fremgangsmåte for behandling av hepatitt C.
- 10 10. Forbindelse for anvendelse ifølge krav 9, i kombinasjon med en nukleosid- eller nukleotidinhibitor av HCV NS5B-polymerase.
11. Farmasøytisk sammensetning ifølge krav 3 eller krav 4 for anvendelse i en fremgangsmåte for behandling av hepatitt C.
- 15 12. Farmasøytisk sammensetning ifølge krav 7 eller krav 8 for anvendelse i en fremgangsmåte for behandling av hepatitt C.